文献速递脊柱关节炎

1860例中轴型脊柱关节炎患者启动司库奇尤单抗治疗的药物留存率、非活动性疾病及应答率:EuroSpA协作组13个登记处的常规诊疗数据

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
PubMed 文献 · RMD Open · 2020-01-01

该研究基于欧洲13个登记处1860例启动司库奇尤单抗治疗的中轴型脊柱关节炎患者真实数据,评估6个月和12个月药物留存率、非活动性疾病/低疾病活动度及应答率。总体6/12个月留存率为82%/72%,生物制剂初治患者疗效持续更优,诊断病程与疗效无关,各登记处间差异显著。

要点

  • 总体6/12个月司库奇尤单抗留存率为82%/72%,各登记处间差异显著。
  • 生物制剂初治患者留存率与应答率数值上高于经治患者,尤以≥2种既往b/tsDMARDs者更低。
  • 诊断病程与司库奇尤单抗疗效无关。

核心结论

  • 在中轴型脊柱关节炎患者中,司库奇尤单抗6个月和12个月药物留存率较高。
  • 司库奇尤单抗疗效在生物制剂初治患者中持续更优,且与诊断病程无关,但各欧洲国家间存在差异。

研究设计与样本

  • 基于欧洲脊柱关节炎研究协作网络13个登记处的真实世界数据汇总分析,共纳入1860例启动司库奇尤单抗常规治疗的中轴型脊柱关节炎患者。
  • 采用Kaplan-Meier法及log-rank检验、Cox回归、χ²检验和logistic回归分析评估6个月和12个月药物留存率、疾病活动度状态及应答率。

主要发现

  • 总体6个月/12个月司库奇尤单抗留存率为82%/72%,各登记处间差异显著(p<0.001),6个月为70-93%,12个月为53-86%。
  • 按既往b/tsDMARDs数量分层,生物制剂初治者6/12个月留存率为90%/73%,1种经治者为83%/73%,≥2种经治者为78%/66%。
  • 总体6个月/12个月BASDAI<4者为51%/51%,ASDAS<1.3者为9%/11%,BASDAI50应答者为53%/47%,ASAS40应答者为28%/22%,ASDAS-CII者为49%/46%,ASDAS-MI者为25%/26%。
  • 所有应答率按既往b/tsDMARDs数量分层差异显著,生物制剂初治患者数值更高,且各登记处间差异显著。
  • 总体而言,诊断病程与司库奇尤单抗疗效无关。

关键数值与推荐

  • 非活动性疾病/低疾病活动度定义:BASDAI<2/<4,ASDAS<1.3/<2.1。
  • 应答率定义:BASDAI50、ASAS20/40、ASDAS临床重要改善(ASDAS-CII)和ASDAS重大改善(ASDAS-MI)。

临床怎么用

  • 真实世界数据显示司库奇尤单抗在中轴型脊柱关节炎中6个月和12个月留存率较高,支持其常规应用。
  • 生物制剂初治患者可能获得更优的留存与应答,临床决策时可参考既往b/tsDMARDs暴露数量。
  • 诊断病程长短不应作为限制司库奇尤单抗使用的依据。
  • 各欧洲登记处间疗效差异提示需结合本地实践与患者特征个体化评估。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Michelsen B, Lindström U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020. PMID: 32950963. doi:10.1136/rmdopen-2020-001280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。